No abstract

No abstract

Acute lymphoblastic leukemia is more common in children, accounting for 85% of childhood leukemias. The incidence of this disease is highest in the three to four year old age group, falling off by ten years. L-asparaginase is an effective antineoplastic agent, used in the acute lymphoblastic leukemia chemotherapy. It has been an integral part of combination chemotherapy protocols of pediatric acute lymphoblastic leukemia for almost 3 decades. It is the first enzyme to be therapeutically effective in human malignant disease. Native or PEGylated L-asparaginase (ASNase or PEG-ASNase) are highly specific for the deamination of L-asparagine (Asn) to aspartic acid and ammonia. Depletion of Laspargine leads to a nutritional deprivation and inhibition of protein biosynthesis, resulting in apoptosis in T-lymphoblastic leukemia's, which require L-aspargine from external sources. This review article comprises detailed information about L-asparaginase historical developments of therapy, its mechanism of action, Advantages of PEG-Lasparaginase versus native preparations, Pharmacokinetic and Pharmacodynamics models of the enzyme, Clinical potential ,its efficacy and host resistance to ASNase.

are designed, synthesized, and evaluated for their in vitro antibacterial and antiproliferative activities. Compound (VIc) exhibits moderate antibacterial activity while derivatives (VIa) and (VIb) display good growth inhibition against A549 and HCT-116 carcinoma cell lines. -(RAJULU*, G. G.; BHOJYA NAIK, H. S.; VISWANADHAN, A.; THIRUVENGADAM, J.; RAJESH, K.; GANESH, S.; JAGADHESHAN, H.; KESAVAN, P. K.; Chem. Pharm. Bull. 62 (2014) 2, 168-175, http://dx.